Skip to Content

Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.

NEW BRUNSWICK, N.J., December 30, 2008 /PRNewswire-FirstCall/ -- Johnson & Johnson today announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals, Inc., a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products. Omrix is expected to operate as a stand-alone entity reporting through ETHICON, Inc., a Johnson & Johnson company.

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,400 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

CONTACT: Media, Jeffrey J. Leebaw, +1-732-524-3350, +1-732-642-6608(mobile), or Bill Price, +1-732-524-6623, +1-732-668-3735 (mobile), orInvestors, Louise Mehrotra, +1-732-524-6491, or Stan Panasewicz,+1-732-524-2524

Web site:

Ticker Symbol: (NYSE:JNJ)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: December 2008